Respiratory

Breath is Life. To breathe is to sing, to be able to work or play, to enjoy living to the fullest. Unfortunately, it is estimated that more than one billion people worldwide suffer from chronic respiratory diseases.

We’re proud of our commitment to respiratory diseases with the introduction of Salbutamol tablets in 1976 and Salbutamol inhaler in 1978 in India. Since then, we have consistently introduced new products for Asthma, Chronic Obstructive Pulmonary Disease (COPD) and Allergic Rhinitis (AR) and more recently in other diseases such as Pulmonary Arterial Hypertension (PAH), lung cancer and Idiopathic Pulmonary Fibrosis (IPF). Our scientists work tirelessly to develop easier-to-use inhaler devices and combination products and devices for monitoring airway diseases. Many of our formulations have made it to the world’s firsts in this therapy. We strive to consistently make developments in the medical fraternity to spread awareness, shatter myths and empower patients to lead fuller lives. Whether millions are affected or a few hundreds, we take our mission in Respiratory very seriously. No effort is spared to make our products and doctor/patient services easier, better, more useful. Cipla Respiratory products are available across the world, prescribed by physicians and consumed by patients in over 100 countries. This marks a testimony to our world-class quality.

Cipla Respiratory. Every breath for our patients, our physicians, our partners.

8 Major Therapeutic Categories

Asthma

Around 50 years ago, people who had asthma in India were treated as if they had an infectious disease. We have been consistently working towards the freedom of asthmatic patients in India. In fact, we pioneered inhalation therapy in India, decades before anyone else. Today, we are helping the world breathe better. We have the world’s largest range of inhaled medication and devices. For every condition, every age and every stage, we have the right medication, the perfect dosage form, the right delivery system for the management of asthma and COPD.

Some of our milestones:

  • DP Haler - The world’s first transparent dry powder inhaler
  • Zerostat V Spacer - World’s first static-free spacer with valve mechanism
  • World’s first single - action, multi-dose (Salmeterol + Fluticasone/Formoterol + Budesonide) Dry Powder Inhaler
  • World’s first breath -  actuated inhaler containing a combination of an inhaled corticosteroid and long-acting beta agonist (Salmeterol + Fluticasone/Formoterol + Budesonide

Allergic Rhinitis

With the rise of nasal allergies, we included Allergic Rhinitis in our spectrum. Our nasal spray is the world’s first combination of an antihistamine and an intranasal steroid (INCS) for allergic rhinitis. We also market a range of nasal steroids and oral antihistamines.

Chronic Obstructive Pulmonary Disease (COPD

With COPD now occupying center stage in the world of respiratory diseases, we have been actively working in this field and have pioneered many formulations that made it to the world’s firsts for COPD management.

  • World’s first Tiotropium in pMDI
  • World’s first breath-actuated inhaler containing a combination of an inhaled steroid and long-acting beta agonist (Salmeterol + Fluticasone/Formoterol + Budesonide)
  • World’s first 3-in-1 combination inhaler
  • World’s first combination of 2 long-acting bronchodilators for COPD (Tiotropium + Formoterol)
  • Besides, we have India’s first nebulised LABA (Formoterol + Fumarate), a new alternative for COPD patients

Moreover, we have developed India’s first nebulised LABA (Formoterol + Fumarate), a new alternative for COPD patients.

Pulmonary Arterial Hypertension (PAH)

We believe that even rare needs care. We are one of the few companies in the world with medicines to treat orphan diseases like Pulmonary Arterial Hypertension. Our portfolio of drugs for this therapy includes the world’s first generic:

  • Bosentan (Sildenafil and Tadalafil)
  • Sildenafil for PAH

Pulmonary Critical Care

Again, we are one of the few companies in the world with injectable antibiotics and doctor support services to treat serious infections in the Intensive Care Unit.

Lung Cancer

We have a specialised division that caters to the treatment of different types of cancer including lung cancer, with non-chemotherapy drugs.

Respiratory Tract Infections

Standing true to our commitment of total lung care, we have the latest generation antibiotics for the management of Respiratory Tract Infections and second line drugs for TB for the international market.

Idiopathic Pulmonary Fibrosis (IPF)

We have taken it upon ourselves to bring rare diseases like IPF to light and have contributed significantly towards the awareness and management of IPF among Pulmonologists and Chest Physicians in India. In fact, we have the world’s first generic Pirfenidone, the first and only approved therapy for IPF.

Notable Achievements

We have to world’s largest range of inhaled medication and devices and we manufacture over 100 million inhalers annually.

Our respiratory products are exported to over 100 countries – every minute someone somewhere is using a form of Cipla medication or a delivery system.

Commitment to Clinical Trials & Clinical Research – Having conducted over 25 drug trials for various drugs and combinations in asthma, COPD, Allergic Rhinitis and inhaler devices, we have provided support for academic research in respiratory medicine. This includes projects related to air quality, epidemiology of obstructive airway disease and the respiratory health status of urban slum dwellers in India.

We founded the Chest Research Foundation in Pune, with the twin objective of promoting respiratory research and respiratory training in India. It is now an independent organization, which collaborates with leading institutions around the world.

CME activities for professional updation of physicians - Unique initiatives for different levels of specialization from primary care to respiratory specialists in the form of workshops, symposia, lectures, and opportunities to interact with global leaders in respiratory medicine.

An array of patient awareness and support programmes under Breathefree – such as www.breathefree.com, a website dedicated to educate patients on asthma, COPD and allergic rhinitis, Breathefree Care & Educators who play an important role in device demonstration and counselling, and Breathefree camps and clinics among other activities.

As you can see, we are constantly pushing the boundaries of science and technology so that someone somewhere in the world breathes better.

Pioneer of many world firsts

DP Haler

The world’s first transparent dry powder inhaler.

Zerostat V Spacer

World’s first static-free spacer with valve mechanism.

World’s first single

action, multi-dose (Salmeterol + Fluticasone/Formoterol + Budesonide) Dry Powder Inhaler

World’s first Tiotropium in MDI for COPD.

World’s first breath-actuated inhaler containing a combination of an inhaled corticosteroid and long-acting beta agonist – (Salmeterol + Fluticasone/Formoterol + Budesonide).

World’s first combination of 2 long-acting bronchodilators (Tiotropium + Formoterol) for COPD.

 

World’s first 3-in-1 combination inhaler for COPD.

World’s first combination of an antihistamine and an intranasal steroid (INCS) for allergic rhinitis in a nasal spray.

World’s first generic Bosentan for management of Pulmonary Arterial Hypertension (PAH).

The world’s first generic Sildenafil for PAH.

The world’s first generic Pirfenidone, the first approved drug for IPF.

The world’s first generic Pirfenidone, the first approved drug for IPF.